A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer

NCT06483425 | Active Not Recruiting

• 1 other identifier: 2024-TJ-OCBiomarker
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.

Conditions

Ovarian Cancer; Biomarker

Outcome Measures

Primary Outcomes (1)

• Biomarker explorarion

  Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer.

  5 years

Study Arms (1)

Ovarian cancer pateitns

Patients diagnosed with Ovarian cancer in Tongji Hospital, Wuhan.

Genetic: Sequencing of DNA, RNA, and Proteins

Interventions

Sequencing of DNA, RNA, and Proteins GENETIC

Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.

Ovarian cancer pateitns

Eligibility Criteria

• Age: 18 Years - 80 Years
• Gender Eligibility Details: Ovarian cancer patients.
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with Ovarian cancer, who are willing to participate in this study and agree to donate samples for sequencing could be included.

You may qualify if:

• Patients diagnosed with ovarian cancer.
• Willingness to undergo biomarker testing.
• Ability to provide informed consent for participation in the study.

You may not qualify if:

• Inability to comply with study requirements or follow-up visits.
• Previous participation in a conflicting clinical trial.

Sponsors & Collaborators

• Tongji Hospital: lead

Study Sites (1)

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood, Tumor, Ascite, and other samples would be collected for sequencing for the identification of biomarkers for OC treatment.

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

RNA; Proteins

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Intervention Hierarchy (Ancestors)

Nucleic Acids; Nucleic Acids, Nucleotides, and Nucleosides; Amino Acids, Peptides, and Proteins

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 24, 2024
• First Posted: July 3, 2024
• Study Start: March 1, 2024
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: July 3, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)